Evidence map›Paper›PMID 37507978›Full record

ArticleAntioxidants (Basel, Switzerland)2023

New NADPH Oxidase 2 Inhibitors Display Potent Activity against Oxidative Stress by Targeting p22

Adriana V Treuer, Mario Faúndez, Roberto Ebensperger, Erwin Hovelmeyer, Ariela Vergara-Jaque, Yunier Perera-Sardiña, Margarita Gutierrez, Roberto Fuentealba, Daniel R González

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Tetrahydrocurcumin Attenuates NaIOAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Adriana V TreuerDepartment of Basic Biomedical Sciences, School of Health Sciences, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile.
Mario FaúndezDepartamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, Santiago 7820436, Chile.
Roberto EbenspergerEscuela de Química y Farmacia, Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago 7510157, Chile.
Erwin HovelmeyerCenter for Bioinformatics, Simulation and Modeling, Faculty of Engineering, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile.
Ariela Vergara-JaqueCenter for Bioinformatics, Simulation and Modeling, Faculty of Engineering, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile.
Yunier Perera-SardiñaDepartment of Basic Biomedical Sciences, School of Health Sciences, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile.ORCID 0000-0001-8205-2565
Margarita GutierrezOrganic Synthesis Laboratory and Biological Activity (LSO-Act-Bio), Institute of Chemistry of Natural Resources, Universidad de Talca, Talca 3460000, Chile.ORCID 0000-0001-9153-2448
Roberto FuentealbaEscuela de Enfermería, Facultad de Salud, Universidad Santo Tomás, Talca 3460000, Chile.ORCID 0000-0002-4017-502X
Daniel R GonzálezDepartment of Basic Biomedical Sciences, School of Health Sciences, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile.ORCID 0000-0002-3437-8998
University of Talca · CLPontificia Universidad Católica de Chile · CLSan Sebastián University · CLUniversidad Santo Tomás · CL

Funding

Agencia Nacional de Investigación y Desarrollo 11170223Agencia Nacional de Investigación y Desarrollo 1150662Agencia Nacional de Investigación y Desarrollo 1220110Agencia Nacional de Investigación y Desarrollo 3180484
6 · The paper itself

Abstract

NADPH oxidase (NOX2) is responsible for reactive oxygen species (ROS) production in neutrophils and has been recognized as a key mediator in inflammatory and cardiovascular pathologies. Nevertheless, there is a lack of specific NOX2 pharmacological inhibitors. In medicinal chemistry, heterocyclic compounds are essential scaffolds for drug design, and among them, indole is a very versatile pharmacophore. We tested the hypothesis that indole heteroaryl-acrylonitrile derivatives may serve as NOX2 inhibitors by evaluating the capacity of 19 of these molecules to inhibit NOX2-derived ROS production in human neutrophils (HL-60 cells). Of these compounds,

Indexed as

heteroaryl-acrylonitrileHL-60 cellsmdxNOX inhibitorsp47phoxreactive oxygen species

Identifiers

PMID37507978
PMCPMC10376059
OpenAlexW4384828126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.